Key result
Lifestyle interventions remain paramount over pharmacological measures for preventing and managing obesity-related cardiovascular risks.
Why the study?
Obesity profoundly impacts cardiovascular health and exacerbates post-COVID-19 cardiovascular complications, necessitating an examination of preventive approaches including lifestyle management and innovative therapies.
Lifestyle interventions remain the cornerstone for preventing and managing cardiovascular risks associated with obesity, particularly in the context of post-COVID-19 complications.
Supports lifestyle primacy in obesity CV risk; leaves open head-to-head RCTs versus pharmacotherapies.
The global prevalence of obesity has surged to epidemic proportions, posing a significant threat to public health in the twenty-first century. Beyond its established association with metabolic diseases, obesity profoundly impacts cardiovascular health, serving as a major risk factor for various cardiovascular illnesses (CVDs), including coronary artery disease, heart failure, hypertension, and stroke. Mechanistically, obesity triggers a cascade of pathophysiological processes, including chronic inflammation and insulin resistance, exacerbating atherosclerosis and endothelial dysfunction. Moreover, obesity correlates with metabolic abnormalities that further elevate the risk of cardiovascular events. As global community has faced the COVID-19 pandemic, and thus, the aftereffects of the pandemic might pose a spectrum of post-viral complications, including cardiovascular sequelae such as myocarditis and arrhythmias. Considering the intersectionality of obesity, COVID-19, and cardiovascular health are imperative, particularly as obese individuals face heightened risks of severe post-COVID-19 effects and subsequent cardiovascular complications. Lifestyle management emerges as a cornerstone in preventing and managing obesity-related cardiovascular risks, encompassing dietary modifications, physical activity, behavioural therapies, and patient education. Embracing innovative approaches, including modulation of gut microbiota and novel drug developments, holds promise in addressing the intricate nexus between obesity and cardiovascular diseases. This review underscores the paramount importance of lifestyle interventions over pharmacological measures, advocating for a comprehensive approach involving healthcare practitioners, researchers, and policymakers to mitigate the long-term cardiovascular consequences of obesity and COVID-19.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2025) conducted a review in Obesity and Cardiovascular Disease. Lifestyle management was evaluated. Lifestyle interventions, including dietary modifications and physical activity, are paramount in preventing and managing obesity-related cardiovascular risks over pharmacological measures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: